Supercharged immune cells take on Hard-to-Treat throat cancer
NCT ID NCT04509726
First seen Jan 21, 2026 · Last updated May 15, 2026 · Updated 13 times
Summary
This early-stage trial tested a new treatment for a type of throat cancer linked to the Epstein-Barr virus. Researchers took patients' own immune cells, engineered them to recognize and attack the virus-infected cancer cells, and also added a feature to boost their cancer-killing power. The study involved 9 people with advanced or returning cancer to find the safest dose and see if the approach could work.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Oncology, Xinqiao Hospital
Chongqing, Chongqing Municipality, 400037, China
Conditions
Explore the condition pages connected to this study.